Trials / Completed
CompletedNCT03099603
A Study of HTD1801 in Healthy Subjects
A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- HighTide Biopharma Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTD1801 | A small molecular compound for the treatment of primary sclerosing cholangitis |
Timeline
- Start date
- 2017-03-24
- Primary completion
- 2017-07-11
- Completion
- 2017-10-03
- First posted
- 2017-04-04
- Last updated
- 2020-07-27
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT03099603. Inclusion in this directory is not an endorsement.